Pretomanid: First Approval
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical)
Link
http://link.springer.com/content/pdf/10.1007/s40265-019-01207-9.pdf
Reference31 articles.
1. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000;405(6789):962–6.
2. TB Alliance. The pandemic: a global threat. 2019. https://www.tballiance.org/why-new-tb-drugs/global-pandemic . Accessed 28 Aug 2019.
3. Gothi D, Joshi JM. Resistant TB: newer drugs and community approach. Recent Pat Anti Infect Drug Disc. 2011;6(1):27–37.
4. Murray S, Mendel C, Spigelman M. TB Alliance regimen development for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016;20(12):38–41.
5. TB Alliance. Novartis sets deal to seek new drugs for fighting TB. 2004. https://www.tballiance.org/news/novartis-sets-deal-seek-new-drugs-fighting-tb . Accessed 27 Aug 2019.
Cited by 136 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Evaluation of the multiple doses thiozonide’s pharmacokinetics in patients diagnosed with pulmonary tuberculosis with multidrug-resistant or extensively drug-resistant <i>Mycobacterium tuberculosis</i>;Pharmacokinetics and Pharmacodynamics;2024-01-22
2. A Drug Discovery Perspective on FDA Expedited Development and Incentive Programs;Journal of Medicinal Chemistry;2024-01-17
3. Synthesis of New 5- or 7-Substituted 3-Nitroimidazo[1,2-a]pyridine Derivatives Using SNAr and Palladium-Catalyzed Reactions To Explore Antiparasitic Structure–Activity Relationships;Synthesis;2023-12-19
4. An Insight on the Prospect of Quinazoline and Quinazolinone Derivatives as Anti-tubercular Agents;Current Organic Synthesis;2023-12
5. A dual-targeting succinate dehydrogenase and F1Fo-ATP synthase inhibitor rapidly sterilizes replicating and non-replicating Mycobacterium tuberculosis;Cell Chemical Biology;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3